GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Virpax Pharmaceuticals
Shares of Virpax, a pharmaceutical company developing non-opioid painkillers, are highly speculative. Their price is driven by news of preclinical and clinical trials and hopes for an alternative to traditional analgesics.
Share prices of companies in the market segment - Pharma psycho
Virpax Pharmaceuticals is a biopharmaceutical company developing non-opioid painkillers using innovative delivery systems. We've categorized it as "Pharma: Psycho." The chart below shows how the market values companies fighting the opioid crisis.
Broad Market Index - GURU.Markets
Virpax Pharmaceuticals is a pharmaceutical company specializing in the development of innovative, non-addictive pain medications. As a key player in its niche, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Virpax's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
VRPX - Daily change in the company's share price Virpax Pharmaceuticals
For Virpax Pharmaceuticals, Inc., a pain medication developer, daily volatility reflects sensitivity to clinical trial data. This metric is an important element for assessing risk in this niche.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Virpax Pharmaceuticals develops non-narcotic analgesics and drugs for the treatment of central nervous system diseases using innovative delivery systems. The chart below shows the volatility in the pharmaceutical sector, which helps assess how the market is responding to VRPX's technologies.
Daily change in the price of a broad market stock, index - GURU.Markets
Virpax Pharmaceuticals develops painkillers, including those based on psychedelics. News of clinical trials in this cutting-edge field triggers sharp stock price movements, which, in turn, contribute to the overall "noise" and market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Virpax Pharmaceuticals
Virpax Pharmaceuticals' year-to-date performance is a story about the development of its non-opioid painkillers. Its 12-month market cap depends entirely on progress in preclinical and clinical trials. The success of its drugs, including nasal sprays, could offer safer alternatives for treating acute and chronic pain.
Annual dynamics of market capitalization of the market segment - Pharma psycho
Virpax, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about its drug delivery platforms. Its stock price will reflect investors' speculative belief in its potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Virpax Pharmaceuticals is a biotech company focused on one specific problem: pain relief without opioids. Its performance relative to the market is purely a matter of anticipation of clinical trial results. Success of its drug could lead to explosive growth, while failure could lead to a near-total loss of value.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Virpax Pharmaceuticals
Virpax is a biopharmaceutical company. Its monthly performance is typical for the sector: it depends on progress in its scientific developments and clinical programs. News about the results of preclinical studies of its pain medications are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
Virpax Pharmaceuticals is a company specializing in the development of non-opioid painkillers and other medications using innovative delivery systems such as sprays and patches. The graph below illustrates the dynamics of the pharmaceutical sector, where the search for alternatives to opioids is a critical priority.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Virpax Pharmaceuticals is a preclinical biotech company developing non-narcotic painkillers. Its shares are a highly speculative bet on the earliest stages of scientific research. Their performance bears no correlation to the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Virpax Pharmaceuticals
Virpax Pharmaceuticals, a company developing non-opioid painkillers, is experiencing high volatility. Weekly stock performance is driven by news about preclinical and clinical trials, reflecting hopes for the development of alternatives to opioids.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Virpax Pharmaceuticals shares, like the entire early-stage biotech sector, move in tandem with investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire industry. The chart shows how the company's shares react to this general "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Virpax Pharmaceuticals is a development-stage biotech company. Its shares exist in a world of their own, where research data dictates everything. The chart clearly demonstrates that VRPX's performance is almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
VRPX - Market capitalization of the company Virpax Pharmaceuticals
The Virpax Pharmaceuticals chart is a financial map of pain management innovation. The market capitalization of this company, which develops non-opioid analgesics in the form of sprays and patches, reflects hopes for safe alternatives. Its volatility reflects the risks and potential of creating new ways to combat pain without the risk of addiction.
VRPX - Share of the company's market capitalization Virpax Pharmaceuticals within the market segment - Pharma psycho
Virpax Pharmaceuticals develops innovative drug delivery systems aimed at non-opioid pain relief. The company's market share in the pharmaceutical sector reflects the expectations for its technologies. Virpax's size reflects investors' bet on developing safer and more effective analgesics.
Market capitalization of the market segment - Pharma psycho
Virpax Pharmaceuticals develops non-opioid painkillers. The chart below shows the overall market capitalization of the entire pharmaceutical industry. Its dynamics provide the backdrop against which Virpax is attempting to address the pressing social problem of opioid addiction.
Market capitalization of all companies included in a broad market index - GURU.Markets
Virpax is a preclinical pharmaceutical company developing new drug delivery systems, including for pain relief and the treatment of viral infections. Its market cap is a bet on future technologies. Its value reflects the potential of its platform, not current revenue.
Book value capitalization of the company, segment and market as a whole
VRPX - Book value capitalization of the company Virpax Pharmaceuticals
Virpax Pharmaceuticals is a preclinical biopharmaceutical company. Its book value is primarily derived from investor cash. The chart below shows how this capital is spent on early research. This is its financial "headroom."
VRPX - Share of the company's book capitalization Virpax Pharmaceuticals within the market segment - Pharma psycho
Virpax Pharmaceuticals develops non-opioid painkillers. Its value lies in its scientific platform and patents. Its share of tangible assets will be minimal, typical for an R&D company whose primary capital is intellectual rather than production.
Market segment balance sheet capitalization - Pharma psycho
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Virpax, which develops non-opioid painkillers, looks like a "lightweight." Its value lies in its unique drug delivery systems and patents, not its manufacturing capacity.
Book value of all companies included in the broad market index - GURU.Markets
Virpax Pharmaceuticals develops non-addictive painkillers in the form of sprays and patches. The company's assets are not its factories, but its patents and research data. The company's balance sheet is the value of finding a safe alternative to opioids that can solve one of the most pressing and real healthcare problems.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Virpax Pharmaceuticals
Virpax's balance sheet is its cash and patents. Its market capitalization is a speculative bet on the success of its non-addictive painkillers. The MvsBCap_Co chart shows how much the "dream" of conquering pain without addiction is worth compared to the company's actual assets.
Market to book capitalization ratio in a market segment - Pharma psycho
Virpax Pharmaceuticals develops non-narcotic painkillers in the form of sprays and patches. Its value lies in its innovative drug delivery systems. The chart shows a speculative estimate of its potential to create an alternative to opioid analgesics.
Market to book capitalization ratio for the market as a whole
Virpax Pharmaceuticals develops innovative drug delivery systems, including for pain relief. Its market valuation is based not on its current assets, but on the potential of its intellectual property. The chart clearly illustrates the high premium the market is willing to pay for advanced pharmaceutical technologies long before they reach market.
Debts of the company, segment and market as a whole
VRPX - Company debts Virpax Pharmaceuticals
For Virpax Pharmaceuticals, a company developing non-opioid painkillers, debt is a source of funding innovation. This chart shows how the company raises capital for preclinical and clinical trials of its drug candidates. Amid the opioid crisis, debt here is an investment in finding safer alternatives.
Market segment debts - Pharma psycho
Virpax Pharmaceuticals is developing new drug delivery systems for pain relief, including opioid-free options. This chart shows how the preclinical pharmaceutical company is funding its early, yet innovative, research that could offer new solutions to one of the most pressing problems in medicine.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Virpax Pharmaceuticals
Virpax Pharmaceuticals develops innovative drug delivery systems, including for pain management. This chart shows the company's reliance on external funding for its research. It reflects the high financial risk inherent in pharmaceutical startups seeking to bring fundamentally new technologies to market.
Market segment debt to market segment book capitalization - Pharma psycho
Virpax Pharmaceuticals is a preclinical company developing non-narcotic painkillers and other drugs with innovative delivery systems. Early-stage R&D requires capital. The chart shows how the company's debt load relates to the market capitalization and risks of the overall pharmaceutical sector.
Debt to book value of all companies in the market
Virpax Pharmaceuticals (VRPX) develops non-opioid painkillers and other medications using innovative delivery systems. The company incurs significant expenses during the R&D phase. This chart shows the overall market debt load. It provides context for understanding why companies like Virpax avoid debt, relying on equity capital.
P/E of the company, segment and market as a whole
P/E - Virpax Pharmaceuticals
This chart shows the valuation of Virpax Pharmaceuticals, a company developing non-opioid painkillers. There is no price-to-earnings ratio. The company's valuation is a pure bet on its ability to offer an effective and safe alternative to opioids. Its performance depends entirely on the results of clinical trials.
P/E of the market segment - Pharma psycho
This is the average P/E for biotech companies. For Virpax, which develops non-opioid analgesics, it serves as a benchmark. It reflects the overall level of investor confidence in the sector, providing context for Virpax's valuation, which is a bet on its ability to offer a solution to a pressing social and medical problem.
P/E of the market as a whole
Virpax Pharmaceuticals develops non-opioid pain medications using innovative delivery systems, such as nasal sprays and patches. The company aims to address opioid addiction. This chart shows the market sentiment in the pharmaceutical sector. It helps understand how the market views the potential of Virpax's technologies to create effective and safe alternatives to opioids.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Virpax Pharmaceuticals
Virpax Pharmaceuticals is a preclinical company developing non-narcotic painkillers and other medications. This chart reflects highly speculative expectations. It shows the long-term future profit analysts are pricing in based solely on the company's R&D potential, not actual revenue.
%20P%2FE%20Virpax%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Virpax-Pharmaceuticals&v=1772513766670 "Chart of the company's future (projected) P/E Virpax Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma psycho
Virpax Pharmaceuticals develops non-opioid pain medications using innovative delivery systems. This chart shows average expectations for the pharmaceutical sector. VRPX's position may indicate the extent to which investors believe in its ability to create an effective and safe alternative to opioids, which is a critical need in medicine.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772513766680 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Virpax Pharmaceuticals is developing non-opioid painkillers. Given the addiction crisis, this is a socially significant area. The company's success depends on regulatory approval. Overall market sentiment, as shown in this chart, impacts capital availability but not the medical need for its products.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513766699 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Virpax Pharmaceuticals
Virpax Pharmaceuticals is a company developing non-narcotic painkillers and other medications using innovative delivery systems. This graph shows the company's path to creating alternatives to opioids. The losses reflect research costs, while future profits depend on the success and approval of its products, which target the vast pain relief market.
Profit of companies in the market segment - Pharma psycho
Virpax Pharmaceuticals develops non-opioid painkillers using innovative delivery systems. Profitability in psychopharmacology, as this chart shows, is increasingly shifting toward finding safe alternatives to opioids. For VRPX, success in creating an effective and non-addictive painkiller could open a huge market and solve a pressing social problem.
Overall market profit
Virpax Pharmaceuticals develops innovative drug delivery methods, such as for opioid-free pain relief. The company's success depends on clinical trials and regulatory approval, not the economic cycle phase shown by this chart. However, the overall market situation and investor sentiment influence its ability to raise capital for its developments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Virpax Pharmaceuticals
Virpax Pharmaceuticals develops non-narcotic painkillers. This chart shows analysts' forecasts for future profits, which are a bet on the success of its developments in the fight against the opioid crisis. This is a financial expression of the company's hopes for the development of effective and safe analgesics.
%20profit%20of%20the%20company%20Virpax%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Virpax-Pharmaceuticals&v=1772513766758 "Graph of future (projected) profit of the company Virpax Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma psycho
Virpax Pharmaceuticals develops non-opioid painkillers using innovative delivery systems, such as nasal sprays. The company aims to address opioid addiction. This chart shows the revenue forecast for the psychopharmaceutical sector, reflecting the urgent need for new, safe analgesics.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772513766765 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Virpax Pharmaceuticals is a preclinical company developing non-narcotic painkillers. Its value is determined solely by the potential of its developments. The overall economic environment, reflected in the forecast, influences its value through investor sentiment. In good times, it is easier to finance such risky projects than in downturns.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513766778 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Virpax Pharmaceuticals
Virpax Pharmaceuticals develops non-narcotic painkillers using innovative delivery systems. Being in the preclinical stage, the company has no revenue. The chart reflects purely speculative investor valuations of its technology. This is a bet that it can offer an effective and safe alternative to opioids.
P/S market segment - Pharma psycho
Virpax Pharmaceuticals develops non-narcotic painkillers using innovative drug delivery systems. The chart shows the average revenue estimate in the pharmaceutical industry. It helps understand how investors value the potential of its products to combat the opioid crisis compared to the industry average.
P/S of the market as a whole
Virpax Pharmaceuticals develops non-opioid painkillers using innovative drug delivery systems. The company aims to address opioid addiction. A graph of average market revenue estimates shows that its value reflects not current revenue, but the enormous social and commercial significance of its potential products.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Virpax Pharmaceuticals
Virpax Pharmaceuticals develops non-narcotic painkillers aimed at addressing opioid addiction. The chart illustrates investors' hopes for a breakthrough in this area. The company is valued based on the potential for huge future revenues from its innovative, non-addictive painkillers.
%20P%2FS%20Virpax%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Virpax-Pharmaceuticals&v=1772513766832 "The graph of the company's future (projected) P/S Virpax Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma psycho
Virpax Pharmaceuticals develops non-narcotic pain medications using innovative drug delivery systems. This chart illustrates average future sales expectations for pharmaceutical companies. It helps investors understand how highly the market values Virpax's technology in creating alternatives to opioid analgesics.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772513766852 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Virpax Pharmaceuticals develops non-opioid painkillers. This is a socially significant and potentially huge niche. This graph of overall revenue expectations is irrelevant. VRPX's success depends solely on the results of clinical trials and regulatory approvals for its innovative products.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513766867 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Virpax Pharmaceuticals
Virpax Pharmaceuticals is a development-stage company focused on developing non-opioid pain medications with innovative delivery systems. Being in the preclinical and clinical stages, it typically does not generate sales revenue. This chart will show the future commercial potential of its developments once they are approved.
Sales of companies in the market segment - Pharma psycho
Virpax Pharmaceuticals develops non-opioid pain medications using innovative drug delivery systems such as sprays and patches. The company strives to create effective and non-addictive alternatives to opioids. This chart shows the sector's total revenue, reflecting the urgent need for new pain treatments.
Overall market sales
Virpax Pharmaceuticals is a biopharmaceutical company developing non-narcotic pain medications. Its success depends on regulatory approval. The overall economic situation, shown in this chart, influences healthcare funding and its interest in alternatives to opioids.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Virpax Pharmaceuticals
Virpax Pharmaceuticals develops non-opioid pain medications using innovative delivery systems. The company's future depends on the success of clinical trials and approval of its products. This timeline reflects market expectations for the commercialization of new, safer pain treatments.
%20sales%20of%20the%20company%20Virpax%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Virpax-Pharmaceuticals&v=1772513766906 "Schedule of future (projected) sales of the company Virpax Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma psycho
Virpax Pharmaceuticals develops non-opioid painkillers with innovative delivery systems, such as nasal sprays and patches. The company strives to offer a safe alternative. The chart shows forecasts for the psychopharmacology sector. Virpax's success depends on addressing the acute opioid crisis.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772513766918 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Virpax Pharmaceuticals develops non-opioid analgesics and central nervous system drugs. The company is in the research phase, and its success depends on funding and trial results. This schedule, reflecting overall economic confidence, influences investor willingness to invest in high-risk, long-cycle pharmaceutical developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513766931 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Virpax Pharmaceuticals
Virpax Pharmaceuticals develops non-opioid painkillers using innovative drug delivery systems. The company is in the preclinical stage, which means high research costs. This chart illustrates the investment required to create safer painkillers that have the potential to be highly profitable.
Market segment marginality - Pharma psycho
Virpax Pharmaceuticals develops non-opioid pain medications using innovative delivery systems. This chart shows the average profitability in the pharmaceutical industry. The company's potential to create opioid alternatives could lead to exceptionally high profitability in the future if its developments are successful.
Market marginality as a whole
Virpax Pharmaceuticals develops non-opioid painkillers using innovative drug delivery systems. The company is in the preclinical stage, meaning it has no revenue and significant R&D expenses. This total revenue chart highlights the gap between the world of biotech startups and the world of cash-generating corporations.
Employees in the company, segment and market as a whole
Number of employees in the company Virpax Pharmaceuticals
Virpax Pharmaceuticals develops innovative drug delivery systems, including for pain treatment. While in the development stage, the company operates with a compact team. This graphic shows a small but highly qualified staff of scientists and experts focused on preclinical and clinical research.
Share of the company's employees Virpax Pharmaceuticals within the market segment - Pharma psycho
Virpax Pharmaceuticals develops innovative, non-addictive pain relief medications using novel drug delivery systems. The company's clinical development staff is small but highly qualified. This chart shows the percentage of scientists in the pain management niche Virpax engages to implement its ambitious R&D program.
Number of employees in the market segment - Pharma psycho
Virpax Pharmaceuticals, Inc. is a specialty pharmaceutical company developing non-opioid pain medications and other drugs using innovative delivery systems. The growth of its small research team, visible in the graph, reflects progress in preclinical and early clinical research.
Number of employees in the market as a whole
Virpax Pharmaceuticals develops innovative drug delivery systems to create non-addictive painkillers. This graph illustrates the trajectory of an early-stage biotech startup. A minimal staff of key scientists and managers is the norm. Any significant increase in the team will be an important signal of progress in preclinical research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals develops non-narcotic pain medications, including those for the central nervous system. For a company with products in development, market value is the valuation of its intellectual property. This chart shows how the market perceives the potential of their proprietary drug delivery systems, which are being developed by a small and focused research team.
%20of%20the%20company%20Virpax%20Pharmaceuticals%20(VRPX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Virpax-Pharmaceuticals-VRPX&v=1772513767023 "Chart of market capitalization per employee (in thousands of dollars) of the company Virpax Pharmaceuticals (VRPX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Virpax Pharmaceuticals develops non-opioid painkillers with innovative delivery systems. As an R&D-stage biotech company, its valuation is based on its technology potential, and its staff is minimal. This chart shows the high valuation investors place on intellectual capital and patents per employee.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772513767044 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Virpax Pharmaceuticals develops non-opioid painkillers with innovative delivery systems. The chart illustrates the valuation of biotech innovation. The high market capitalization per employee reflects the enormous need for effective and safe analgesics and investor confidence in the company's technology platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513767064 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Virpax Pharmaceuticals (VRPX)
Virpax is a clinical-stage biopharmaceutical company developing non-opioid painkillers (including nasal sprays). The company is not profitable. This chart shows the net loss (R&D costs) per scientist working on developing a highly sought-after alternative to opioids.
%20Chart%20Virpax%20Pharmaceuticals%20(VRPX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Virpax-Pharmaceuticals-VRPX&v=1772513767068 "Company Profit Per Employee (in thousands of dollars) Chart Virpax Pharmaceuticals (VRPX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Virpax Pharmaceuticals is a preclinical company developing non-opioid painkillers using innovative delivery systems. This chart shows cash burn per employee. It serves as a benchmark for assessing how intensively Virpax is investing in its R&D programs to create alternatives to traditional painkillers, where the need for innovation is enormous.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772513767069 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Virpax Pharmaceuticals is a clinical-stage biotech focused on developing non-opioid painkillers using innovative delivery systems. The company is not commercially profitable. This graph shows a negative value—the investment (loss) per employee working on developing an opioid alternative.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513767083 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals is developing non-opioid painkillers. For a company in the development stage, this graph will reflect key commercialization milestones. Increased revenue per employee will likely result from a licensing agreement with a major pharmaceutical company.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Virpax-Pharmaceuticals-VRPX&v=1772513767109 "Sales chart per company employee Virpax Pharmaceuticals (VRPX)")
Sales per employee in the market segment - Pharma psycho
Virpax Pharmaceuticals (VRPX) is a preclinical-stage company developing non-opioid painkillers and CNS medications. The company has no clinical-stage products, let alone sales. This graph doesn't reflect their value. Staff productivity here would be zero. All value lies in patents and early scientific data.
Sales per employee for the market as a whole
Virpax is a pharmaceutical company developing non-opioid painkillers. At the R&D stage, this metric reflects investment in science. A team of scientists is working on new drug delivery systems. This graph will only begin to grow if their developments pass trials and are commercialized.
Short shares by company, segment and market as a whole
Shares shorted by company Virpax Pharmaceuticals (VRPX)
Virpax Pharma (VRPX) is a pharmaceutical company developing non-opioid painkillers and CNS medications using new delivery systems (such as nasal). This chart shows bearish bets. Bears doubt their delivery technologies will be effective or that the company will be able to successfully complete clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Virpax-Pharmaceuticals-VRPX&v=1772513767150 "Short Shares Chart for the Company Virpax Pharmaceuticals (VRPX)")
Shares shorted by market segment - Pharma psycho
Virpax Pharmaceuticals is a company developing new drug delivery methods, including for pain relief and the treatment of psychoemotional disorders, while avoiding opioids. This chart illustrates the overall bearish sentiment in the pharmaceutical sector focused on pain and CNS treatments. It reflects investor skepticism of the sector, possibly due to high regulatory barriers or clinical trial failures.
Shares shorted by the overall market
Virpax Pharmaceuticals is an early-stage biotech company. This chart illustrates the overall market pessimism. As fear mounts, investors sell off biotech microcaps en masse. They see VRPX as a money-burner on high-risk R&D and prefer to exit the stock without waiting for news on trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals (VRPX) develops non-opioid painkillers using innovative delivery systems (such as a nasal spray). This is a highly sought-after area. This chart measures the strength of speculative moves. It shows when the stock is "overheated" (above 70) on FDA news or "oversold" (below 30) due to delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Virpax-Pharmaceuticals-VRPX&v=1772513767186 "RSI 14 indicator chart for the company's stock Virpax Pharmaceuticals (VRPX)")
RSI 14 Market Segment - Pharma psycho
Virpax is a "biotech" company that delivers to the brain (and beyond). Their specialty is intranasal (nasal spray) drug delivery (for pain, epilepsy) directly to the brain. The "Pharma psycho" (biotech/delivery) sector thrives on R&D. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is VRPX's growth a niche product or just a general hype?
RSI 14 for the overall market
Virpax Pharmaceuticals (VRPX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VRPX (Virpax Pharmaceuticals)
Virpax Pharmaceuticals is a biotech company developing non-narcotic painkillers (sprays, patches) and antiviral agents. This chart shows the average 12-month forecast of analysts. It represents their collective speculative bet on the success of the R&D portfolio in the preclinical stage.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VRPX-Virpax-Pharmaceuticals&v=1772513767218 "A chart showing analyst consensus forecasts for the expected stock price. VRPX (Virpax Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price VRPX (Virpax Pharmaceuticals)
Virpax (VRPX) is a biotech company developing non-opioid painkillers using innovative delivery systems (sprays, patches). This chart measures the gap between the current price and the consensus target price. It shows the potential (and risks) analysts see in their R&D portfolio for the massive pain market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VRPX-Virpax-Pharmaceuticals&v=1772513767219 "A chart showing the difference between the consensus forecast and the actual stock price. VRPX (Virpax Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Virpax Pharmaceuticals is a biotech company developing non-opioid painkillers using new delivery systems (nasal spray, patch). This chart shows general expectations for the psychopharma sector. It reflects whether experts believe a breakthrough in "safe" painkillers is possible.
Analysts' consensus forecast for the overall market share price
Virpax Pharma (VRPX) is a "pharmaceutical engineer." It's a micro-cap R&D startup that doesn't invent molecules, but rather seeks *new* delivery methods (sprays, patches) for pain treatment. This chart shows the overall risk appetite. It reflects how much investors are willing to invest in the earliest, pre-clinical R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Virpax Pharmaceuticals
Virpax Pharmaceuticals is a biotech company focused on developing non-opioid painkillers using innovative delivery systems (e.g., intranasal). This company is in early-stage development. This chart is a comprehensive barometer reflecting market perception of the potential of their technologies, the risks of preclinical and clinical trials, and funding needs.
AKIMA Market Segment Index - Pharma psycho
Virpax (VRPX) is a psycho- and pain-focused pharma company. They don't invent new molecules, but rather develop innovative delivery methods (such as a nasal spray) for the treatment of pain and PTSD. This chart compares their composite index to the psycho-pharma sector average.
The AKIM Index for the overall market
Virpax Pharmaceuticals is a company developing non-narcotic pain management therapies and drug delivery systems (nasal sprays, patches). This chart, reflecting the market average, provides a macro-scale backdrop. It helps assess how this micro-scale story, in the preclinical and clinical stages, compares to overall economic trends.
